ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease

ImmunityBio, Inc.

2025-Q1 EPS reported -$0.15 revenue$16,517,000

Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).
Unit sales volume in Q1 2025 grew 150% QoQ exceeding FY2024 total; March up 69% MoM.
Submitted sBLA to FDA for ANKTIVA+BCG in BCG-unresponsive NMIBC papillary disease; 93% cystectomy avoidance at 20.7 months.
Submitted Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia after RMAT designation in Q1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.